Cargando…

Case Report: Cetuximab and nivolumab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy

We present the case of a 60-year-old man with unresectable cutaneous squamous cell carcinoma (cSCC) of the sternal area, which was not amenable to radiation therapy (stage III, T3N0M0). The treatment history of this patient is remarkable as the disease had progressed through all lines of conventiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Sernicola, Alvise, Lampitelli, Salvatore, Marraffa, Federica, Maddalena, Patrizia, Grassi, Sara, Richetta, Antonio Giovanni, Calvieri, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993817/
https://www.ncbi.nlm.nih.gov/pubmed/32047600
http://dx.doi.org/10.12688/f1000research.19149.2
_version_ 1783493108620591104
author Sernicola, Alvise
Lampitelli, Salvatore
Marraffa, Federica
Maddalena, Patrizia
Grassi, Sara
Richetta, Antonio Giovanni
Calvieri, Stefano
author_facet Sernicola, Alvise
Lampitelli, Salvatore
Marraffa, Federica
Maddalena, Patrizia
Grassi, Sara
Richetta, Antonio Giovanni
Calvieri, Stefano
author_sort Sernicola, Alvise
collection PubMed
description We present the case of a 60-year-old man with unresectable cutaneous squamous cell carcinoma (cSCC) of the sternal area, which was not amenable to radiation therapy (stage III, T3N0M0). The treatment history of this patient is remarkable as the disease had progressed through all lines of conventional therapy established in the literature. The patient was treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab for 35 cycles and restaged after 12 months of therapy with a whole body CT scan, documenting stage IV disease (T3N2bM1). The use of cetuximab as a single agent was effective for a limited time and we decided to initiate combination therapy with cetuximab and nivolumab. Restaging after six months of this combination regimen documented stable disease.
format Online
Article
Text
id pubmed-6993817
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-69938172020-02-10 Case Report: Cetuximab and nivolumab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy Sernicola, Alvise Lampitelli, Salvatore Marraffa, Federica Maddalena, Patrizia Grassi, Sara Richetta, Antonio Giovanni Calvieri, Stefano F1000Res Case Report We present the case of a 60-year-old man with unresectable cutaneous squamous cell carcinoma (cSCC) of the sternal area, which was not amenable to radiation therapy (stage III, T3N0M0). The treatment history of this patient is remarkable as the disease had progressed through all lines of conventional therapy established in the literature. The patient was treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab for 35 cycles and restaged after 12 months of therapy with a whole body CT scan, documenting stage IV disease (T3N2bM1). The use of cetuximab as a single agent was effective for a limited time and we decided to initiate combination therapy with cetuximab and nivolumab. Restaging after six months of this combination regimen documented stable disease. F1000 Research Limited 2019-12-31 /pmc/articles/PMC6993817/ /pubmed/32047600 http://dx.doi.org/10.12688/f1000research.19149.2 Text en Copyright: © 2019 Sernicola A et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Sernicola, Alvise
Lampitelli, Salvatore
Marraffa, Federica
Maddalena, Patrizia
Grassi, Sara
Richetta, Antonio Giovanni
Calvieri, Stefano
Case Report: Cetuximab and nivolumab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy
title Case Report: Cetuximab and nivolumab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy
title_full Case Report: Cetuximab and nivolumab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy
title_fullStr Case Report: Cetuximab and nivolumab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy
title_full_unstemmed Case Report: Cetuximab and nivolumab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy
title_short Case Report: Cetuximab and nivolumab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy
title_sort case report: cetuximab and nivolumab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993817/
https://www.ncbi.nlm.nih.gov/pubmed/32047600
http://dx.doi.org/10.12688/f1000research.19149.2
work_keys_str_mv AT sernicolaalvise casereportcetuximabandnivolumabuseinadvancedcutaneoussquamouscellcarcinomaresistanttochemotherapy
AT lampitellisalvatore casereportcetuximabandnivolumabuseinadvancedcutaneoussquamouscellcarcinomaresistanttochemotherapy
AT marraffafederica casereportcetuximabandnivolumabuseinadvancedcutaneoussquamouscellcarcinomaresistanttochemotherapy
AT maddalenapatrizia casereportcetuximabandnivolumabuseinadvancedcutaneoussquamouscellcarcinomaresistanttochemotherapy
AT grassisara casereportcetuximabandnivolumabuseinadvancedcutaneoussquamouscellcarcinomaresistanttochemotherapy
AT richettaantoniogiovanni casereportcetuximabandnivolumabuseinadvancedcutaneoussquamouscellcarcinomaresistanttochemotherapy
AT calvieristefano casereportcetuximabandnivolumabuseinadvancedcutaneoussquamouscellcarcinomaresistanttochemotherapy